References
- Anastasiou E , LorentzKO, SteinGJ, MitchellPD. Prehistoric schistosomiasis parasite found in the Middle East. Lancet Infect. Dis.14 (7), 553–554 (2014).
- World Health Organization . Schistosomiasis Fact sheet No. 115. www.who.int/mediacentre
- Mostafa MH , SheweitaSA, O'ConnorPJ. Relationship between schistosomiasis and bladder cancer. Clin. Microbiol. Rev.12 (1), 97–111 (1999).
- Feldmeier H , KrantzI, PoggenseeG. Female genital schistosomiasis as a risk-factor for the transmission of HIV. Int. J. STD AIDS5 (5), 368–372 (1994).
- Kjetland EF , NdhlovuPD, GomoEet al. Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS20 (4), 593–600 (2006).
- Mbabazi PS , AndanO, FitzgeraldDW, ChitsuloL, EngelsD, DownsJA. Examining the relationship between urogenital schistosomiasis and HIV infection. PLoS Negl. Trop. Dis.5 (12), e1396 (2011).
- Colley DG , SecorWE. Immunology of human schistosomiasis. Parasite Immunol.36 (8), 347–357 (2014).
- ClinicalTrials Database: NCT02337855 . https://clinicaltrials.gov/ct2/show/NCT02337855
- World Health Organization . Preventative Chemotherapy in Human Helminthiasis. Geneva. http://whqlibdoc.who.int
- Merck KGaA . Corporate Social Responsibility Report 2012 – Philanthropy and product donations. Darmstadt. http://reports.merckgroup.com
- Chai JY . Praziquantel treatment in trematode and cestode infections: an update. Infect. Chemother.45 (1), 32–43 (2013).
- Pica-Mattoccia L , CioliD. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int. J. Parasitol.34 (4), 527–533 (2004).
- Botros S , Pica-MattocciaL, WilliamS, El-LakkaniN, CioliD. Effect of praziquantel on the immature stages of Schistosoma haematobium. Int. J. Parasitol.35 (13), 1453–1457 (2005).
- TI Pharma . Pediatric Praziquantel Consortium awarded US $1.86 million GHIT grant. www.tipharma.com
- Wang W , WangL, LiangYS. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol. Res.111 (5), 1871–1877 (2012).
- Nwaka S , HudsonA. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov.5 (11), 941–955 (2006).
- Sissoko MS , DaboA, TraoreHet al. Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS ONE4 (10), e6732 (2009).
- Basra A , Mombo-NgomaG, MelserMCet al. Efficacy of mefloquine intermittent preventive treatment in pregnancy against Schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trial. Clin. Infect. Dis.56 (6), e68–e75 (2013).
- Keiser J , SilueKD, AdiossanLKet al. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl. Trop. Dis.8 (7), e2975 (2014).
- Keiser J , N'GuessanNA, AdoubrynKDet al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin. Infect. Dis.50 (9), 1205–1213 (2010).
- World Health Organization . WHO Model List of Essential Medicines – 18th List. Geneva. http://apps.who.int
- ClinicalTrials Database: NCT01054651 https://clinicaltrials.gov/ct2/show/NCT01054651
- Obonyo CO , MuokEM, MwinziPN, Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial. Lancet Infect Dis10 (9), 603–611 (2010).
- ClinicalTrials Database: NCT00510159 https://clinicaltrials.gov/ct2/show/NCT00510159
- ClinicalTrials Database: NCT01132248 https://clinicaltrials.gov/ct2/show/NCT01132248
- ISRCTN registry . Praziquantel, praziquantel plus mefloquine and praziquantel plus mefloquine-artesunate in the treatment of schistosomiasis.http://www.isrctn.com/ISRCTN00393859
- ClinicalTrials Database: NCT01529710 https://clinicaltrials.gov/ct2/show/NCT01529710
- ISRCTN registry . Mefloquine and artesunate against schistosomiasis.www.isrctn.com/ISRCTN06498763
- ClinicalTrials Database: NCT01459146 https://clinicaltrials.gov/ct2/show/NCT01459146
- World Health Organization . International Clinical Trials Registry Platform (ICTRP) Search Portal. (2014).http://apps.who.int/trialsearch/Default.aspx
- Keiser J , UtzingerJ. Antimalarials in the treatment of schistosomiasis. Curr. Pharm. Des.18 (24), 3531–3538 (2012).
- Pedrique B , Strub-WourgaftN, SomeCet al. The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment. Lancet Glob. Health1 (6), e371–e379 (2013).
- Dickson M , GagnonJP. The cost of new drug discovery and development. Discov. Med.4, 172 (2004).
- Pharmaceutical Research and Manufacturers of America® (PhRMA) . Clinical trials: the phases of drug testing and approval. www.phrma.org/innovation
- Adam I , ElhardelloOA, ElhadiMO, AbdallaE, ElmardiKA, JansenFH. The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria. Ann. Trop. Med. Parasitol.102 (1), 39–44 (2008).
- Boulanger D , DiengY, CisseBet al. Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Trans. R. Soc. Trop. Med. Hyg.101 (2), 113–116 (2007).
- Xiao SH , CattoBA. In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni. Antimicrob. Agents Chemother.33 (9), 1557–1562 (1989).
- Keiser J , CholletJ, XiaoSHet al. Mefloquine – an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl. Trop. Dis.3 (1), e350 (2009).
- Utzinger J , CholletJ, YouJ, MeiJ, TannerM, XiaoS. Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals. Acta Trop.80 (1), 9–18 (2001).
- Keiser J , ManneckT, VargasM. Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J. Antimicrob. Chemother.66 (8), 1791–1797 (2011).
- Special Program for Research and Training in Tropical Diseases (TDR) . The TDR Targets Database, v5. http://tdrtargets.org
- Rojo-Arreola L , LongT, AsarnowD, SuzukiBM, SinghR, CaffreyCR. Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS ONE9 (1), e87594 (2014).
- Salvador-Recatala V , GreenbergRM. Calcium channels of schistosomes: unresolved questions and unexpected answers. Wiley Interdiscip. Rev. Membr. Transp. Signal.1 (1), 85–93 (2012).
- Cabezas-Cruz A , LancelotJ, CabyS, OliveiraG, PierceRJ. Epigenetic control of gene function in schistosomes: a source of therapeutic targets?Front. Genet.5, 317 (2014).
- Morel M , VanderstraeteM, CailliauK, LescuyerA, LancelotJ, DissousC. Compound library screening identified Akt/PKB kinase pathway inhibitors as potential key molecules for the development of new chemotherapeutics against schistosomiasis. Int. J. Parasitol. Drugs Drug Resist.4 (3), 256–266 (2014).
- Tobert JA . Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov.2 (7), 517–526 (2003).
- Ghamami N , ChiangSH, DormuthC, WrightJM. Time course for blood pressure lowering of dihydropyridine calcium channel blockers. Cochrane Database Syst. Rev.8, CD010052 (2014).
- Atadja PW . HDAC inhibitors and cancer therapy. Prog. Drug Res.67, 175–195 (2011).
- Garcia-Echeverria C , SellersWR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene27 (41), 5511–5526 (2008).
- Access to Medicine Index Foundation . Access to Medicine Index 2014. Haarlem. (2014). www.accesstomedicineindex.org
- Abdulla MH , RuelasDS, WolffBet al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl. Trop. Dis.3 (7), e478 (2009).
- Marek M , KannanS, HauserATet al. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog.9 (9), e1003645 (2013).
- Merck Sharp & Dohme Corp. www.merck.com/index.html
- BIO Ventures for Global Health . Current Programs: WIPO Re:Search. (2015). www.bvgh.org/Current-Programs/WIPO-ReSearch.aspx
- Dent J , RamamoorthiR, GraefK, NelsonLM, WichardJC. WIPO Re:Search: a consortium catalyzing research and product development for neglected tropical diseases. Pharm. Pat. Anal.2 (5), 591–596 (2013).
- Ramamoorthi R , GraefKM, DentJ. WIPO Re:Search: accelerating anthelmintic development through cross-sector partnerships. Int. J. Parasitol. Drugs Drug Resist.4 (3), 220–225 (2014).
- BIO Ventures for Global Health . WIPO Re:Search partnership stories (2012–2013). Seattle. (2014).
- World Intellectual Property Organization . WIPO Re:Search (2015). www.wipo.int/research/en/
- World Intellectual Property Organization . WIPO Re:Search Guiding Principles. www.wipo.int
- Chen GZ , FosterL, BennettJL. Antischistosomal action of mevinolin: evidence that 3-hydroxy-methylglutaryl-coenzyme a reductase activity in Schistosoma mansoni is vital for parasite survival. Naunyn-Schmiedebergs Arch. Pharmacol.342 (4), 477–482 (1990).